EP4728103A2 - Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation - Google Patents
Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentationInfo
- Publication number
- EP4728103A2 EP4728103A2 EP24826511.8A EP24826511A EP4728103A2 EP 4728103 A2 EP4728103 A2 EP 4728103A2 EP 24826511 A EP24826511 A EP 24826511A EP 4728103 A2 EP4728103 A2 EP 4728103A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cfdna
- cancer
- fragments
- fragment
- cpg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Software Systems (AREA)
- Bioinformatics & Computational Biology (AREA)
- Data Mining & Analysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Databases & Information Systems (AREA)
- Bioethics (AREA)
- General Physics & Mathematics (AREA)
- Public Health (AREA)
- Mathematical Physics (AREA)
- Computing Systems (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363521666P | 2023-06-17 | 2023-06-17 | |
| PCT/US2024/034360 WO2024263526A2 (en) | 2023-06-17 | 2024-06-17 | Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4728103A2 true EP4728103A2 (en) | 2026-04-22 |
Family
ID=93936238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP24826511.8A Pending EP4728103A2 (en) | 2023-06-17 | 2024-06-17 | Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4728103A2 (he) |
| KR (1) | KR20260025833A (he) |
| CN (1) | CN121693582A (he) |
| AU (1) | AU2024312665A1 (he) |
| CO (1) | CO2026000372A2 (he) |
| IL (1) | IL325231A (he) |
| WO (1) | WO2024263526A2 (he) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120279994B (zh) * | 2025-03-04 | 2026-03-27 | 深圳市海普洛斯生物科技有限公司 | 一种基于全基因组测序筛选外周血中癌症特异性cfDNA片段特征组合的方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019222657A1 (en) * | 2018-05-18 | 2019-11-21 | The Johns Hopkins University | Cell-free dna for assessing and/or treating cancer |
| MX2024006820A (es) * | 2021-12-15 | 2024-08-15 | Univ Johns Hopkins | Mutacion del genoma completo de molecula unica y perfiles de fragmentacion de acido desoxirribonucleico (adn) libre de celula. |
-
2024
- 2024-06-17 EP EP24826511.8A patent/EP4728103A2/en active Pending
- 2024-06-17 WO PCT/US2024/034360 patent/WO2024263526A2/en not_active Ceased
- 2024-06-17 CN CN202480044661.6A patent/CN121693582A/zh active Pending
- 2024-06-17 AU AU2024312665A patent/AU2024312665A1/en active Pending
- 2024-06-17 KR KR1020267001181A patent/KR20260025833A/ko active Pending
-
2025
- 2025-12-09 IL IL325231A patent/IL325231A/he unknown
-
2026
- 2026-01-15 CO CONC2026/0000372A patent/CO2026000372A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024312665A1 (en) | 2025-12-18 |
| CN121693582A (zh) | 2026-03-17 |
| KR20260025833A (ko) | 2026-02-24 |
| WO2024263526A3 (en) | 2025-04-17 |
| WO2024263526A9 (en) | 2025-10-09 |
| WO2024263526A2 (en) | 2024-12-26 |
| CO2026000372A2 (es) | 2026-01-23 |
| IL325231A (he) | 2026-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saleh et al. | The biology of ependymomas and emerging novel therapies | |
| Chmielik et al. | Heterogeneity of thyroid cancer | |
| Ennishi et al. | CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy | |
| Musto et al. | 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde | |
| Griffith et al. | Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia | |
| US20240060141A1 (en) | Detection of lung cancer using cell-free dna fragmentation | |
| US20250131982A1 (en) | Single molecule genome-wide mutation and fragmentation profiles of cell-free dna | |
| Yoon et al. | Real-world efficacy of 5-azacytidine as salvage chemotherapy for angioimmunoblastic T-cell lymphoma | |
| CA3213049A1 (en) | Targeted therapies in cancer | |
| US20240141437A1 (en) | Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy | |
| EP4728103A2 (en) | Dna methylation and gene expression as determinants of genome-wide cell-free dna fragmentation | |
| KR20250128956A (ko) | 무세포 dna 단편화를 사용하는 간암 검출 | |
| Gagné et al. | Acquired SMARCA4 alterations: An uncommon contributor to cancer progression in lung adenocarcinomas | |
| Nelles et al. | Real world molecular characterisation and clonal evolution of acute myeloid leukaemia reveals therapeutic opportunities and challenges | |
| Colombino et al. | Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck District | |
| WO2025213107A2 (en) | Detection and treatment of ovarian cancer | |
| Ayass et al. | Transcriptome-Based Treatment for Melanoma With Brain Metastasis: A Case Report | |
| Kim et al. | Yoo-Na Kim1, Kyunglim Lee1, Eunhyang Park2, Junsik Park1, Yong Jae Lee1, Eun Ji Nam1, Sang Wun Kim1, Sunghoon Kim1, Young Tae Kim1 and Jung-Yun Lee1 | |
| CN116940994A (zh) | 使用细胞游离dna片段化检测肺癌 | |
| Tarantino et al. | Multiomic profiling of a unique in-transit melanoma cohort identifies melanoma differentiation as predictor of tumor progression and therapy response | |
| Lewandowski et al. | Circulating tumor DNA–from biology to potential clinical applications in diffuse large B-cell lymphomas | |
| 임가영 | Molecular subtyping of ependymoma and prognostic impact of Ki-67 | |
| Hurtado et al. | EGFR Amplification in a Patient with Glioblastoma: A Case Report and Review of the Literature. | |
| CN117321225A (zh) | 癌症的靶向疗法 | |
| VALGIUSTI et al. | EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20260114 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |